AZD8055

Catalog No.S1555

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Cited by 40 Publications

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )
Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )
Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )
Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

8 Customer Reviews

PC3-LN4 cells were treated with GSK690693 (5 uM) alone, or in combination with PP242 (2 uM) or AZD8055 (1 uM) for 24 h, and immunoblotting performed.

Cancer Res 2013 73(11), 3402-11. AZD8055 purchased from Selleck.

mTOR kinase inhibitor AZD8055 activates PI3K accompanied with induction of expression of EGFR, HER2, HER3 and IRS1. Serum-deprived CHO-EGFP-AKT cells were incubated with 50 nM AZD8055 for 24 hr. The EGFP signal was detected using confocal microscopy. The white arrows indicate EGFP-AKT located on cellular membrane.

Int J Cancer 2014 135(10), 2462-74. AZD8055 purchased from Selleck.
HUVEC were treated with either RAD001 or AZD8055 before PA treatment. p53, GPX1, p53 acetylation, and subcellular PTEN were analyzed with corresponding antibodies. The blot is a representative of the results of three experiments. Values (mean盨D) are expressed as fold over untreated control. *p<0.05 versus their corresponding control groups in the one-way ANOVA.

Antioxid Redox Signal 2014 20(9), 1382-95. AZD8055 purchased from Selleck.

CSCs^+24/44/ESA at 5,000 cells per well with stem cell culture media in triplicate in an ultra-low adhesion plate were treated with 5 umol/L BMS-777607, 1 umol/L AZD8055 alone, or in their different combinations. Cells were cultured for 72 hours. Cell viability was determined by the MTS assay. Percentages of polyploid cells were determined by counting 300 cells from two different regions. Results shown here were from one of two experiments with similar results.

Mol Cancer Ther 2014 13(1), 37-48. AZD8055 purchased from Selleck.
mTOR, P70S6K1, 4E-BP1 and PCNA activation in the basilar artery of SAH. Top, Western blotting bands of antibodies, bottom, density of the protein band from each group. A, mTOR activation in the basilar artery demonstrated an elevated expression of mTOR on day 7 following SAH in SAH and SAH+DMSO animals. The mTOR inhibitors, Rapamycin and AZD8055 reduced the enhanced expression of mTOR (pb0.05, ANOVA). B. P70S6K1 activation. C. 4E-BP1 activation. D. PCNA activation. Rapamycin and AZD8055 significantly decreased the expression of P70S6K1, 4E-BP1 and PCNA compared with the SAH and SAH+DMSO (pb0.05, respectively; ANOVA). There was no significant difference between the two inhibitors in mTOR, P70S6K1, 4E-BP1 and PCNA expression.

Exp Neurol 2012 233, 799-806. AZD8055 purchased from Selleck.

Induction of TCTP expression through 5-FU or oxaliplatin is inhibited by mTOR kinase inhibitors. HCT116 cells were treated for 48 h with 5-FU or oxaliplatin at the indicated concentrations. Where indicated, AZD 8055 (100 nM) or PP242 (1 μM) were added. TCTP levels were assessed by western blotting; signals were quantified and normalised against α-tubulin as a loading control. As a readout of mTOR activity, phosphorylation of the ribosomal protein S6 at Ser 240/244 was assessed using a phospho-specific antibody. a. Representative western blots demonstrating the alteration of the levels of TCTP protein and of phospho-ribosomal protein S6, respectively, in relation to the drug concentration.

Cell Commun Signal, 2017, 15(1):9. AZD8055 purchased from Selleck.
(A) HCT116 or MDA-MB-468 cells were treated with 500 nM AZD8055 for the indicated times. Cell lysates were immunoblotted with the indicated antibodies. (B) HCT116 or MDA-MB-468 cells were treated with 50 nM rapamycin. 500 nM AZD8055, 1 uM MK2206 or dimethyl sulfoxide (DMSO) as control for 12 h. Cell lysates were immunoblotted with the indicated antibodies.

Oncotarget 2014 5(15), 6015-27. AZD8055 purchased from Selleck.

After starved in serum-free medium for 24h , A549 cells incubated with the indicated concentrations of AZD8055 for 3h , followed by 20-minute stimolation of 100ng/ml EGF

Dr. Zhang of Tianjin Medical University. AZD8055 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	NV:5XZN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwMEKzN\|Eh\|ryP	M{nqbXNCVkeHUh?=
NCI-H720	M1P0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\EZ2lEPTB;MD6wNlk{QCEQvF2=	NWe4e5R3W0GQR1XS
KARPAS-45	NGTlRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwMEOzO\|Eh\|ryP	NGHF[nhUSU6JRWK=
EW-3	NIP6coJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDBXGVIUUN3ME2wMlA1ODV4IN88US=>	NIDyRlVUSU6JRWK=
SBC-1	NVz6bXMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHYXmtKSzVyPUCuNFQ2QDFizszN	NGC3ZoNUSU6JRWK=
NCI-H209	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTBwMEW0OVMh\|ryP	MV3TRW5ITVJ?
EoL-1-cell	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTNTWM2OD1yLkC2OVY6KM7:TR?=	NF3MXGZUSU6JRWK=
H9	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXFW3RKSzVyPUCuNFY3QTJizszN	M3j4OHNCVkeHUh?=
AN3-CA	Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLkTWM2OD1yLkC3PVUyKM7:TR?=	MmXQV2FPT0WU
HH	M1qwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jGVWlEPTB;MD6wPFAxQSEQvF2=	NFLv[mdUSU6JRWK=
KU812	Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrYTWM2OD1yLkC4NFQ{KM7:TR?=	MoHpV2FPT0WU
DU-4475	M4DFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDGN4VSUUN3ME2wMlA5ODR5IN88US=>	M3WyWXNCVkeHUh?=
CTV-1	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvzVHFKSzVyPUCuNFg3PDFizszN	MU\TRW5ITVJ?
BV-173	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zZN2lEPTB;MD6wPVA3OSEQvF2=	NHTM[pVUSU6JRWK=
ES5	NFPqTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTnTWM2OD1yLkC5N\|Uh\|ryP	NVXXPJIyW0GQR1XS
G-402	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDrTWM2OD1yLkC5PVgh\|ryP	NV7CeHE3W0GQR1XS
MV-4-11	NYXjSplbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXMRoFKSzVyPUCuNVA{PDdizszN	MVLTRW5ITVJ?
NB69	NHX1eoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTBwMUO1JO69VQ>?	MYXTRW5ITVJ?
EGI-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofJTWM2OD1yLkGzOVMyKM7:TR?=	NETWd\|JUSU6JRWK=
EW-18	M4P6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfyVXZKSzVyPUCuNVQxPzNizszN	NGLXWIpUSU6JRWK=
ME-180	M1vMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYC1TVJxUUN3ME2wMlE1PjhzIN88US=>	MXXTRW5ITVJ?
D-283MED	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rkZmlEPTB;MD6xOFczOyEQvF2=	MkS5V2FPT0WU
NB14	M2Trdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLMTWM2OD1yLkG2OFQ4KM7:TR?=	Mmm1V2FPT0WU
Ramos-2G6-4C10	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrnNVZPUUN3ME2wMlE3QTh\|IN88US=>	MnzLV2FPT0WU
NBsusSR	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;1Xm5xUUN3ME2wMlE4ODF7IN88US=>	NF6ySlZUSU6JRWK=
LAMA-84	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrFfGVKSzVyPUCuNVgxOzJizszN	NEnFXVZUSU6JRWK=
NCI-H1581	NIThWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPHdXF4UUN3ME2wMlE5QTZ4IN88US=>	MkHRV2FPT0WU
A204	M{HveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofWTWM2OD1yLkG4PVch\|ryP	MWjTRW5ITVJ?
A549	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DaVmlEPTB;MD6xPVU2KM7:TR?=	M{fBXXNCVkeHUh?=
CAL-51	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXz2XWF7UUN3ME2wMlE6PjVzIN88US=>	NFLue3NUSU6JRWK=
NKM-1	NGjtR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTBwMkCwNlkh\|ryP	MnHpV2FPT0WU
LoVo	M1XKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTUTWM2OD1yLkKwNlAzKM7:TR?=	NY\tXI1wW0GQR1XS
HAL-01	NIjBc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rFdmlEPTB;MD6yNFI6PyEQvF2=	NVLRe2xHW0GQR1XS
HCC2218	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHtZmhKSzVyPUCuNlA3QDhizszN	NWTDTZBEW0GQR1XS
BEN	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPMTWM2OD1yLkKxNlk{KM7:TR?=	NUGyNHo3W0GQR1XS
LC-2-ad	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXDPFJXUUN3ME2wMlIzODh2IN88US=>	NF7mZolUSU6JRWK=
LXF-289	M2TSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHWT3hDUUN3ME2wMlI2ODRzIN88US=>	NX;4fVN{W0GQR1XS
HGC-27	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPmcWtvUUN3ME2wMlI3PDF2IN88US=>	NYXLOHlEW0GQR1XS
LK-2	M{H2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEm5cFRKSzVyPUCuNlY5OjRizszN	NUPDeWppW0GQR1XS
CTB-1	M{jOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTBwMkeyNVUh\|ryP	M{HJWHNCVkeHUh?=
697	NIH1[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\5cmlEPTB;MD6yO\|M3PyEQvF2=	MXPTRW5ITVJ?
ES7	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TjW2lEPTB;MD6yO\|M5OyEQvF2=	MXHTRW5ITVJ?
MG-63	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\yNGlEPTB;MD6yO\|QxPyEQvF2=	MV3TRW5ITVJ?
T47D	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXG4V\|ZUUUN3ME2wMlI4PDd3IN88US=>	MoSwV2FPT0WU
RPMI-8226	MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHP3fmVKSzVyPUCuNlg2QDlizszN	Mo\nV2FPT0WU
NCI-H292	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTBwMkmxOlQh\|ryP	M4rKeXNCVkeHUh?=
HT	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHHXYl6UUN3ME2wMlI6OzhizszN	M3HJSnNCVkeHUh?=
A3-KAW	NGTMdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLld\|BKSzVyPUCuNlk4PCEQvF2=	MXfTRW5ITVJ?
LB2241-RCC	Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTBwM{CxPVgh\|ryP	NV\s[JJUW0GQR1XS
BB65-RCC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfHeIRjUUN3ME2wMlMxQDB3IN88US=>	MV\TRW5ITVJ?
G-401	NFrzRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j2Z2lEPTB;MD6zNFk5PiEQvF2=	MVfTRW5ITVJ?
TYK-nu	NVPrO3hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XIRmlEPTB;MD6zNVg3PCEQvF2=	M3n3bHNCVkeHUh?=
NCI-SNU-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPvPWJ5UUN3ME2wMlMzOzNzIN88US=>	M{nXN3NCVkeHUh?=
CHL-1	NWTL[ldYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIL6W\|JKSzVyPUCuN\|I4ODNizszN	Ml\JV2FPT0WU
P30-OHK	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4n6bmlEPTB;MD6zNlcxPSEQvF2=	NXX3N3FlW0GQR1XS
PA-1	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHBbWdKSzVyPUCuN\|M3OTlizszN	NEPwVo5USU6JRWK=
LB1047-RCC	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFKw[ndKSzVyPUCuN\|QxPDdizszN	M3LEN3NCVkeHUh?=
EM-2	NWLiSGo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3zTWM2OD1yLkO0NVg5KM7:TR?=	MV\TRW5ITVJ?
VA-ES-BJ	NGHXflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnP4TWM2OD1yLkO0NlY5KM7:TR?=	MmHmV2FPT0WU
NCI-H520	M2jVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTBwM{S4N\|Qh\|ryP	MWfTRW5ITVJ?
ECC10	NWToS2tqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDsTWM2OD1yLkO1NFM2KM7:TR?=	MU\TRW5ITVJ?
LNCaP-Clone-FGC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2D5[2lEPTB;MD6zOVMyPCEQvF2=	MmnSV2FPT0WU
ES8	NWHDbnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPITWM2OD1yLkO2OVU{KM7:TR?=	MWjTRW5ITVJ?
HuO-3N1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPwTWM2OD1yLkO4N\|c6KM7:TR?=	MmPLV2FPT0WU
L-363	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTBwM{mwNlYh\|ryP	M{OybHNCVkeHUh?=
SK-LU-1	M4r1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnMfZNtUUN3ME2wMlM6OjB6IN88US=>	MknWV2FPT0WU
MCF7	NILrXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrGdXlKSzVyPUCuOFA2OyEQvF2=	M3HGOXNCVkeHUh?=
HuO9	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3r6d2lEPTB;MD60NFY3PyEQvF2=	M3L3VXNCVkeHUh?=
BHT-101	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTBwNEC3PFch\|ryP	NUXJUpF1W0GQR1XS
MZ2-MEL	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX75SIpYUUN3ME2wMlQxQDh{IN88US=>	M1;ac3NCVkeHUh?=
NOS-1	NHPBPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTEfY1XUUN3ME2wMlQyODd2IN88US=>	M3q4UHNCVkeHUh?=
NEC8	NVL4VJJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIWyNY9KSzVyPUCuOFE3QTVizszN	M2jCXHNCVkeHUh?=
COR-L88	MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUOxNo1PUUN3ME2wMlQzOjZ5IN88US=>	MYLTRW5ITVJ?
MFM-223	NEG4Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGKxRWtKSzVyPUCuOFI3OTdizszN	M1;CN3NCVkeHUh?=
HSC-3	NFftTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3j[FNKSzVyPUCuOFI6ODhizszN	NWnmemZGW0GQR1XS
OVCAR-5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;PTWM2OD1yLkSyPVM{KM7:TR?=	M4HHNHNCVkeHUh?=
MFE-280	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;BTWM2OD1yLkSzNFMzKM7:TR?=	NXHoOIViW0GQR1XS
KP-N-YS	NVvo[5RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH4WYNbUUN3ME2wMlQ{ODdizszN	NH7wV4VUSU6JRWK=
EPLC-272H	NW\G[lkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3XV29wUUN3ME2wMlQ{ODd5IN88US=>	MXvTRW5ITVJ?
KE-37	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4OwPGlEPTB;MD60N\|I1PyEQvF2=	M1\2PXNCVkeHUh?=
HuH-7	M1PkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwNEOzO\|Ih\|ryP	NXzZO484W0GQR1XS
CHP-212	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTBwNEO2PVch\|ryP	M163V3NCVkeHUh?=
SK-MES-1	M{LicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvtTWM2OD1yLkSzPFQ5KM7:TR?=	M374RXNCVkeHUh?=
SJSA-1	M3ThO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;zOWlEPTB;MD60OFU2PCEQvF2=	NHPRR5pUSU6JRWK=
QIMR-WIL	M2XnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;RNWlEPTB;MD60OVE2KM7:TR?=	M4XyXXNCVkeHUh?=
ES4	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PQOGlEPTB;MD60OVM{PiEQvF2=	MnjvV2FPT0WU
TI-73	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTBwNEW2PFYh\|ryP	NGH4[HlUSU6JRWK=
COLO-684	NWPNTWhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfndVQ6UUN3ME2wMlQ2PzJ4IN88US=>	MWHTRW5ITVJ?
GCIY	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;RXWxXUUN3ME2wMlQ2PzV2IN88US=>	MV;TRW5ITVJ?
JVM-3	M1;W[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDXTWM2OD1yLkS2NlkzKM7:TR?=	M3myRXNCVkeHUh?=
MPP-89	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfFemxXUUN3ME2wMlQ3QTR5IN88US=>	NX20T2ZXW0GQR1XS
M14	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTBwNEexO{DPxE1?	NVvD[2dyW0GQR1XS
SW962	M{jWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPRb3dKSzVyPUCuOFcyQSEQvF2=	NXTPUVl{W0GQR1XS
VM-CUB-1	NFLSfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHsPI9oUUN3ME2wMlQ4Ojh4IN88US=>	MX7TRW5ITVJ?
A101D	M2\Sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPMTWM2OD1yLkS4PVY5KM7:TR?=	MYLTRW5ITVJ?
DB	M{[z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkS5TWM2OD1yLkWwNFIyKM7:TR?=	MV3TRW5ITVJ?
KNS-62	NUXNW4xST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\tbWlEPTB;MD61NFU3QCEQvF2=	M1fNTHNCVkeHUh?=
NCI-H460	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTBwNUC1PVch\|ryP	M4LlfHNCVkeHUh?=
MDA-MB-361	NUDvN4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwNUC4O{DPxE1?	MkG5V2FPT0WU
DOK	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTBbYFSUUN3ME2wMlUyOzN\|IN88US=>	NYrjfWVnW0GQR1XS
CAL-39	NH;oN\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmezTWM2OD1yLkWyNlY5KM7:TR?=	M1nZSXNCVkeHUh?=
HT-1080	NET2clhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHqUVRKSzVyPUCuOVI2PDNizszN	NYH1UJpYW0GQR1XS
GR-ST	M2\6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTBwNUOwNVUh\|ryP	M3jVWnNCVkeHUh?=
J-RT3-T3-5	NVzvNoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHXVJdKSzVyPUCuOVMyQTVizszN	MXTTRW5ITVJ?
NCI-H1793	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jufGlEPTB;MD61N\|Q1PyEQvF2=	NF:yOpFUSU6JRWK=
NCI-H1355	NGHDfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4r0UmlEPTB;MD61N\|g4QCEQvF2=	M{fSV3NCVkeHUh?=
YH-13	NIW5ZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwNUS5N\|gh\|ryP	NIHOS4ZUSU6JRWK=
LOXIMVI	NHvXT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXqd21KUUN3ME2wMlU2OTJ\|IN88US=>	MmnLV2FPT0WU
ES1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIr0NoVKSzVyPUCuOVU2OThizszN	MUTTRW5ITVJ?
GAMG	M3nZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLlTWM2OD1yLkW1OlU5KM7:TR?=	NVvPXmdbW0GQR1XS
SK-MEL-28	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfRNGpKSzVyPUCuOVU6OSEQvF2=	MULTRW5ITVJ?
KG-1	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTNTWM2OD1yLkW2PFg1KM7:TR?=	MYLTRW5ITVJ?
HOS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTONodsUUN3ME2wMlU4OTl{IN88US=>	Mn7mV2FPT0WU
PANC-08-13	NWmyNnV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTBwNUezPFkh\|ryP	MoHWV2FPT0WU
SW780	M4TIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7BNploUUN3ME2wMlU4PTl3IN88US=>	NWD3XWlCW0GQR1XS
MDA-MB-175-VII	NUTyUGd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmCwTWM2OD1yLkW3O\|QyKM7:TR?=	M1zMbXNCVkeHUh?=
MSTO-211H	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHm2e\|hKSzVyPUCuOVc4PTFizszN	NHmzOVhUSU6JRWK=
ML-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVT0OFJpUUN3ME2wMlU5PDd6IN88US=>	M4fBTHNCVkeHUh?=
SCC-4	M1nHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljZTWM2OD1yLkW4OVQyKM7:TR?=	NHj5bYlUSU6JRWK=
NCI-H1048	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfwdY5HUUN3ME2wMlU5PjR3IN88US=>	NVPYemRGW0GQR1XS
NCI-H28	NXfMT\|dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPJdGVKSzVyPUCuOVg3PzVizszN	MXTTRW5ITVJ?
BCPAP	M{DMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTBwNUi3PVEh\|ryP	M{\x[HNCVkeHUh?=
PC-14	MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jD[2lEPTB;MD61PFk4KM7:TR?=	MlXDV2FPT0WU
OAW-42	NXjwcFBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTBwNUmxOlIh\|ryP	NF3TcnVUSU6JRWK=
IA-LM	NVq2RYVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjHOo41UUN3ME2wMlU6PjB7IN88US=>	MorPV2FPT0WU
Hs-578-T	M4DSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPIT21KSzVyPUCuOVk5PTFizszN	NYrOPG1FW0GQR1XS
H4	NITBVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTBwNkCwPVQh\|ryP	MnXxV2FPT0WU
HL-60	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrWfIxmUUN3ME2wMlYxOzVzIN88US=>	NIHSW4lUSU6JRWK=
NCI-H1437	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTBwNkC2NVkh\|ryP	MnzjV2FPT0WU
KGN	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXlTWM2OD1yLk[xNFQ6KM7:TR?=	NXPiO2hZW0GQR1XS
NCI-H2452	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nv[mlEPTB;MD62NVkyPyEQvF2=	NYfKdJo5W0GQR1XS
BFTC-905	NHrCc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXrTYxKSzVyPUCuOlIyOjZizszN	MkG0V2FPT0WU
CAMA-1	NYLGUoVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzENok5UUN3ME2wMlYzOTV{IN88US=>	MnjpV2FPT0WU
SK-NEP-1	NYft[4QxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjJO4FKSzVyPUCuOlI2ODJizszN	NGTUWFBUSU6JRWK=
NCI-H522	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInGSHJKSzVyPUCuOlI6QTJizszN	M1Lj[HNCVkeHUh?=
SW1710	NVjxW4RsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVf0OWFuUUN3ME2wMlY{OTZ5IN88US=>	MoXrV2FPT0WU
RVH-421	NIO4O5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDWTWM2OD1yLk[zOlM6KM7:TR?=	M3LGe3NCVkeHUh?=
SK-MEL-2	NYDZUYtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17HcmlEPTB;MD62OFE2OyEQvF2=	MnP3V2FPT0WU
KYSE-150	MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvLV4pKSzVyPUCuOlYyQDZizszN	NUP3O4ZjW0GQR1XS
MOLT-13	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTqb3NKSzVyPUCuOlY2OzdizszN	MWXTRW5ITVJ?
SK-OV-3	MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWi3b445UUN3ME2wMlY4OTh5IN88US=>	M1n5fHNCVkeHUh?=
IGROV-1	NYHJbZJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkT0TWM2OD1yLk[3OFUh\|ryP	NF3FUmxUSU6JRWK=
MOLT-4	NHTEOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFL1dnlKSzVyPUCuOlc3QDlizszN	M2nSRXNCVkeHUh?=
MEL-HO	NHjPWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnxSXBVUUN3ME2wMlY4PzV{IN88US=>	NYjHV202W0GQR1XS
MDA-MB-157	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUCxOohNUUN3ME2wMlY4QDFizszN	MWHTRW5ITVJ?
MN-60	NFnWWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;4Ro5NUUN3ME2wMlY4QDR4IN88US=>	NEmwfW9USU6JRWK=
EFO-27	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwNke5O\|kh\|ryP	M4XZTHNCVkeHUh?=
HO-1-N-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTBwNkiwOlQh\|ryP	NXHWfVRkW0GQR1XS
TE-5	M1zPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX24[\|ltUUN3ME2wMlY5PDB3IN88US=>	M2ToOHNCVkeHUh?=
EW-22	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIG0UodKSzVyPUCuOlg1PDRizszN	NH3qNodUSU6JRWK=
SW982	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PEW2lEPTB;MD62PFUxOSEQvF2=	NW\K[WdoW0GQR1XS
SF295	NYezOGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXTNIFKSzVyPUCuOlg2ODdizszN	MV\TRW5ITVJ?
WM-115	M2DkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVP5[Wh1UUN3ME2wMlY5QTJ2IN88US=>	M4fVbnNCVkeHUh?=
COLO-800	Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnxcJRKSzVyPUCuOlk5OTNizszN	M2PtfXNCVkeHUh?=
NTERA-S-cl-D1	M3HGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1y3cGlEPTB;MD63NFA3OyEQvF2=	MmjFV2FPT0WU
NCI-H1648	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7RTWM2OD1yLkewNVc{KM7:TR?=	NEjMdnZUSU6JRWK=
NB5	M1nWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrnZVJ3UUN3ME2wMlcxOzF7IN88US=>	MXLTRW5ITVJ?
ATN-1	NInMPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTBwN{C1PUDPxE1?	MX3TRW5ITVJ?
NUGC-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\tNWxvUUN3ME2wMlcxPjlzIN88US=>	NYjEOHYzW0GQR1XS
22RV1	NFPkN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTBwN{C3NVch\|ryP	NFrWSHVUSU6JRWK=
8305C	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTBwN{C3OVUh\|ryP	NFXISHZUSU6JRWK=
EFM-19	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DmVGlEPTB;MD63NFg1PyEQvF2=	MVXTRW5ITVJ?
PC-3	M{T1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTBwN{KyN{DPxE1?	NGO3WVVUSU6JRWK=
C32	NHHRU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwN{K0PFQh\|ryP	MU\TRW5ITVJ?
MC-IXC	NX7OUmZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1WwRWlEPTB;MD63NlcyQCEQvF2=	NGHCbVhUSU6JRWK=
OMC-1	M4TyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXzcIJGUUN3ME2wMlczPzN6IN88US=>	NH72VlhUSU6JRWK=
HTC-C3	NGrYR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\uW3dKSzVyPUCuO\|MyPzJizszN	M3XnN3NCVkeHUh?=
RPMI-7951	NES5OJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Pmb2lEPTB;MD63N\|U{OyEQvF2=	M1OxfnNCVkeHUh?=
AsPC-1	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;NNmlEPTB;MD63N\|c6PSEQvF2=	MXjTRW5ITVJ?
CAKI-1	M{\yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLlTWM2OD1yLke0OlI6KM7:TR?=	M3LsTnNCVkeHUh?=
MHH-PREB-1	NH31WIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\YZ\|ZpUUN3ME2wMlc1PzN4IN88US=>	M1HmSXNCVkeHUh?=
HLE	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTBwN{S4OFQh\|ryP	MmjQV2FPT0WU
A375	NUjmeWw6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7lTWM2OD1yLke1NVk{KM7:TR?=	NF:2W2hUSU6JRWK=
RS4-11	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\kVZJKSzVyPUCuO\|U6PDNizszN	NYX1TZdZW0GQR1XS
U-2-OS	M3jSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDlOJJKSzVyPUCuO\|U6PyEQvF2=	NFLXd3FUSU6JRWK=
NCI-H747	NHX3SpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXy[mJYUUN3ME2wMlc2QTlzIN88US=>	NXzSZnNJW0GQR1XS
NCI-H1623	M175U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;HXZE6UUN3ME2wMlc3OjZzIN88US=>	NFr3RoZUSU6JRWK=
DMS-273	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUGwPHZpUUN3ME2wMlc3QTJ{IN88US=>	NV3MRZpRW0GQR1XS
PSN1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTBwN{ewOVch\|ryP	NUDPSXVEW0GQR1XS
LU-99A	MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HIPWlEPTB;MD63O\|Y1QSEQvF2=	MX3TRW5ITVJ?
CAL-12T	NGHVS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorsTWM2OD1yLke4NFI6KM7:TR?=	Mo\PV2FPT0WU
KYSE-140	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvNTWM2OD1yLke4NVY5KM7:TR?=	NUPWcJViW0GQR1XS
VMRC-RCZ	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M370RmlEPTB;MD63PFQ5OiEQvF2=	NGP2c5BUSU6JRWK=
Ca9-22	M4TyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLNRWh7UUN3ME2wMlc5PzN4IN88US=>	M{XGbnNCVkeHUh?=
NCI-H1563	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHCZnJKSzVyPUCuO\|g6OjZizszN	NVLySZVqW0GQR1XS
NCI-H650	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLoOHZrUUN3ME2wMlc6OTR2IN88US=>	M1\xOnNCVkeHUh?=
DOHH-2	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXpTWM2OD1yLke5N\|Mh\|ryP	M1ixTHNCVkeHUh?=
OE33	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7SelNpUUN3ME2wMlc6QTF2IN88US=>	NHfKZpFUSU6JRWK=
CAL-62	M1nOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\ZO4lTUUN3ME2wMlc6QTJ2IN88US=>	MoTFV2FPT0WU
NCI-H1770	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17QZ2lEPTB;MD64NFIyKM7:TR?=	MXLTRW5ITVJ?
SN12C	NEPN[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwOEC2Olgh\|ryP	M{nObnNCVkeHUh?=
HPAF-II	M2nhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrSbGtKSzVyPUCuPFA4QTRizszN	MnrFV2FPT0WU
SNU-423	M2rBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvwTWM2OD1yLkixOFIzKM7:TR?=	NHjLOY5USU6JRWK=
A704	NIC3V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUD3NpFkUUN3ME2wMlgyPzl6IN88US=>	MYDTRW5ITVJ?
OVCAR-4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33Mc2lEPTB;MD64NVkyOSEQvF2=	MkW1V2FPT0WU
NCI-H2347	MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTBwOEK0NFEh\|ryP	M13NSXNCVkeHUh?=
OCUB-M	M3P5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDGT4kxUUN3ME2wMlgzPjd3IN88US=>	NGrwdVhUSU6JRWK=
KYSE-450	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmr6TWM2OD1yLkiyO\|I2KM7:TR?=	Mn\3V2FPT0WU
PFSK-1	NWnqbFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPHTWM2OD1yLkizNFM6KM7:TR?=	MkK3V2FPT0WU
A431	NETIZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2e1VGlEPTB;MD64N\|EyPiEQvF2=	MUnTRW5ITVJ?
MHH-ES-1	M{PvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYP3TnpUUUN3ME2wMlg{PDV5IN88US=>	NFfYVHFUSU6JRWK=
HD-MY-Z	MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETZd3BKSzVyPUCuPFQxQTJizszN	MXjTRW5ITVJ?
RT-112	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTBwOES5N\|ch\|ryP	MoK4V2FPT0WU
KU-19-19	M33hS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3scFRyUUN3ME2wMlg2OTJzIN88US=>	NVG0cZk6W0GQR1XS
HCC1569	M33WTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEe2WGlKSzVyPUCuPFUzODdizszN	MWLTRW5ITVJ?
RPMI-8866	NIfnboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwOEW4NlIh\|ryP	MVHTRW5ITVJ?
CAL-120	M{HwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnuzTWM2OD1yLki2NFQyKM7:TR?=	MV\TRW5ITVJ?
CAL-33	M3nhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXPTWM2OD1yLki2OFk2KM7:TR?=	NV:ycFJSW0GQR1XS
RKO	M2TEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTBwOE[4NVch\|ryP	MWnTRW5ITVJ?
HCC1419	NV\wNoRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTBwOE[5Nlgh\|ryP	M1XzRXNCVkeHUh?=
CP50-MEL-B	NYLEeHA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYn6b5NzUUN3ME2wMlg5Ozh2IN88US=>	MWnTRW5ITVJ?
BPH-1	NFn3ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzHepd6UUN3ME2wMlg5Ozl3IN88US=>	NV7Pd3o6W0GQR1XS
SF126	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\m[mlEPTB;MD64PFcyPCEQvF2=	MlPZV2FPT0WU
BHY	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTBwOEi3N\|Qh\|ryP	NVW1eVJFW0GQR1XS
BxPC-3	MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HPOmlEPTB;MD64PFg{OyEQvF2=	MYDTRW5ITVJ?
ETK-1	NGfWZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTBwOEmzO\|Ih\|ryP	MnLUV2FPT0WU
NCI-H1573	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrWTWM2OD1yLkmwNlI6KM7:TR?=	NFvObGNUSU6JRWK=
C-33-A	NWewd3dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnf5TWM2OD1yLkmwOFQzKM7:TR?=	NEfZZVRUSU6JRWK=
UACC-893	NELwV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnwPWo3UUN3ME2wMlkzQDV3IN88US=>	MoqxV2FPT0WU
RXF393	NIrjeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTzWoU2UUN3ME2wMlkzQDl5IN88US=>	MoLSV2FPT0WU
MIA-PaCa-2	NH2zcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzGcmdKSzVyPUCuPVI6OjJizszN	MnvyV2FPT0WU
HCC1806	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTBwOUOyOVYh\|ryP	MkLNV2FPT0WU
DMS-114	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfCTWM2OD1yLkmzOlc4KM7:TR?=	MUTTRW5ITVJ?
MOLT-16	NFL1UmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3PeFZKSzVyPUCuPVM5PDVizszN	MmrVV2FPT0WU
ACN	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XYTmlEPTB;MD65OFI4PyEQvF2=	MUPTRW5ITVJ?
SNU-449	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTBwOUW5NlQh\|ryP	M2TvbHNCVkeHUh?=
A427	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\YTWM2OD1yLkm2NVk5KM7:TR?=	MXzTRW5ITVJ?
DEL	NX;IZnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXoOpRvUUN3ME2wMlk3Pzd\|IN88US=>	NXjIRmRuW0GQR1XS
NCI-H1792	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTBwOUexNFEh\|ryP	Mmf4V2FPT0WU
A2058	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\OTWM2OD1yLkm3N\|Yh\|ryP	NHrleZVUSU6JRWK=
SW13	NG\UbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TPSGlEPTB;MD65PFM6OiEQvF2=	M33mRXNCVkeHUh?=
T98G	M{nG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFwMEGzOlQh\|ryP	M1;Ec3NCVkeHUh?=
LU-134-A	NWjUTFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFwMEK2O\|Uh\|ryP	NEfPdGNUSU6JRWK=
GI-ME-N	M4jIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLOcldKSzVyPUGuNFI5OjdizszN	M{TlRXNCVkeHUh?=
D-423MG	MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnUOJpKSzVyPUGuNFI6PjNizszN	NYnZSYV2W0GQR1XS
PANC-03-27	M3XoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInHfHRKSzVyPUGuNFMyPDFizszN	NWrxfY04W0GQR1XS
P12-ICHIKAWA	MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlSzTWM2OD1zLkCzOFA3KM7:TR?=	MVPTRW5ITVJ?
SCH	M17MXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\XRZFKSzVyPUGuNFM1PSEQvF2=	NX;teYxvW0GQR1XS
D-566MG	NIHBSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fV[WlEPTB;MT6wOlczPiEQvF2=	MXzTRW5ITVJ?
OS-RC-2	NWHOZZR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkD5TWM2OD1zLkC3PVQh\|ryP	MmLKV2FPT0WU
KOSC-2	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1y3O2lEPTB;MT6wPFAzOSEQvF2=	NF6zZZBUSU6JRWK=
SH-4	MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHy1[mFKSzVyPUGuNFg1OzFizszN	M4WyVHNCVkeHUh?=
786-0	M{[3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFwMEi5N\|Qh\|ryP	MX3TRW5ITVJ?
Mewo	NUCzbVJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HlNWlEPTB;MT6wPVI1QCEQvF2=	Mn\UV2FPT0WU
AGS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTFwMEm0OVkh\|ryP	MlPJV2FPT0WU
Daoy	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnoeGdKSzVyPUGuNFk3OjhizszN	Mm\2V2FPT0WU
SW48	NHHP[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjDTYdQUUN3ME2xMlExQTFzIN88US=>	MlvSV2FPT0WU
KYSE-180	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DHOmlEPTB;MT6xNVAzOSEQvF2=	NIGxc\|FUSU6JRWK=
NH-12	M1m3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwMUGyN\|ch\|ryP	MmHZV2FPT0WU
BE-13	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHDTWM2OD1zLkGxO\|U6KM7:TR?=	NYK3fnFZW0GQR1XS
ES3	NY\QUWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\3VXZKSzVyPUGuNVMyPzFizszN	NXHDb3FmW0GQR1XS
NCI-H1092	NVm4N4ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTFwMUO0JO69VQ>?	M{GxeXNCVkeHUh?=
NCI-H1755	NH7vO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjFPHdKSzVyPUGuNVM6PDFizszN	M2XNd3NCVkeHUh?=
EKVX	M2\icWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnv5TWM2OD1zLkG0NFAyKM7:TR?=	M4T2XnNCVkeHUh?=
NB13	NITscmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jGW2lEPTB;MT6xOFQ2KM7:TR?=	NEK2OHRUSU6JRWK=
NCI-H2405	M2jhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnrTWM2OD1zLkG0OVc1KM7:TR?=	NUPYV3V3W0GQR1XS
LS-411N	NGrMWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVu2VIxpUUN3ME2xMlE2ODF5IN88US=>	MnzZV2FPT0WU
MDA-MB-453	NWP2TYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTFwMUW2NlQh\|ryP	NYm5Um1YW0GQR1XS
SCC-15	M2T0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzuRYd4UUN3ME2xMlE3QTV4IN88US=>	NUPwe5hiW0GQR1XS
C2BBe1	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXj3cZNrUUN3ME2xMlE4ODV4IN88US=>	MnnSV2FPT0WU
HT-144	M{mzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFwMUewO{DPxE1?	M1LhRnNCVkeHUh?=
HEC-1	NIjwVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFwMUe2Nlch\|ryP	MXTTRW5ITVJ?
HCE-T	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnhTWM2OD1zLkG3PVg{KM7:TR?=	MYXTRW5ITVJ?
IST-MEL1	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkOyTWM2OD1zLkG5NFgzKM7:TR?=	NH7JS21USU6JRWK=
Detroit562	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mni3TWM2OD1zLkG5OFM6KM7:TR?=	NWHicVdRW0GQR1XS
A4-Fuk	MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDacpZTUUN3ME2xMlIxPDRzIN88US=>	M4rIW3NCVkeHUh?=
HDLM-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzNTWM2OD1zLkKxN\|I3KM7:TR?=	NFiwS4lUSU6JRWK=
MKN7	M3LHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LXVmlEPTB;MT6yNVcxOiEQvF2=	NXLRWHplW0GQR1XS
MDA-MB-415	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTteIZKSzVyPUGuNlE4ODJizszN	NEPIRoRUSU6JRWK=
BT-20	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK5elJVUUN3ME2xMlIzPDR2IN88US=>	M33F[XNCVkeHUh?=
NCI-H2030	NILBRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rGXmlEPTB;MT6yOFExPiEQvF2=	Ml;JV2FPT0WU
LS-123	MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUmz[4xYUUN3ME2xMlI1PzV\|IN88US=>	NFX0[HFUSU6JRWK=
SK-MEL-3	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2mxTmlEPTB;MT6yOFc4PiEQvF2=	MXvTRW5ITVJ?
KS-1	Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzHTWM2OD1zLkK1NVcyKM7:TR?=	Mm\6V2FPT0WU
LU-65	M1m4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwMkW2NFYh\|ryP	NI\ObY1USU6JRWK=
NCI-H596	M{HEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTFwMkW5Nlkh\|ryP	NHq3Z41USU6JRWK=
KYSE-410	NWLaPI9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPlTGtKSzVyPUGuNlcxOTRizszN	NWPrTVVyW0GQR1XS
NCI-H2228	M2XXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvncYVKSzVyPUGuNlcyPjdizszN	NXq1ZmQ6W0GQR1XS
LN-405	MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofzTWM2OD1zLkK4NFIyKM7:TR?=	Mki4V2FPT0WU
8505C	Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M321NWlEPTB;MT6yPFgzOyEQvF2=	MofNV2FPT0WU
BFTC-909	M3XQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHSdXNTUUN3ME2xMlI6PDN2IN88US=>	M3HUXHNCVkeHUh?=
OC-314	M1zqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIC3WFdKSzVyPUGuNlk6OjlizszN	NUPEOI5EW0GQR1XS
NMC-G1	NX\DWFlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTFwM{GxN\|Uh\|ryP	NHTGWINUSU6JRWK=
SKG-IIIa	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnIOFZtUUN3ME2xMlMyPDJ6IN88US=>	M373NXNCVkeHUh?=
GAK	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\xTWM2OD1zLkOxPFU5KM7:TR?=	NHHpbFdUSU6JRWK=
D-263MG	NVroeYRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFwM{K2OFEh\|ryP	NHfwSolUSU6JRWK=
NCI-H446	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTjTWM2OD1zLkOyPVAzKM7:TR?=	M{XacXNCVkeHUh?=
TGBC1TKB	NHLWO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PPdWlEPTB;MT6zNlk6QCEQvF2=	NH\2dmJUSU6JRWK=
GCT	M4i0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUO2N5VHUUN3ME2xMlM1OzR3IN88US=>	MW\TRW5ITVJ?
COR-L23	M1vVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPiR5NKSzVyPUGuN\|Q5PDVizszN	NX74c3YyW0GQR1XS
TK10	NV;JeVFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETWcIJKSzVyPUGuN\|U4QTdizszN	MlzIV2FPT0WU
ES6	NXTqfmFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\LZlBKSzVyPUGuN\|Y{PzZizszN	Mn2yV2FPT0WU
SW1088	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\LPGxKSzVyPUGuN\|Y3OTJizszN	Ml\0V2FPT0WU
AM-38	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fNOWlEPTB;MT6zO\|E6QSEQvF2=	M3TlUnNCVkeHUh?=
CHP-134	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fTVWlEPTB;MT6zO\|g1PCEQvF2=	NXHafXVnW0GQR1XS
SW872	NHvyfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHT1XWZKSzVyPUGuN\|g2PTVizszN	MVzTRW5ITVJ?
LB831-BLC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUO1O4pOUUN3ME2xMlM6ODZ5IN88US=>	NGTSS4RUSU6JRWK=
TE-12	M3jpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXMUpZqUUN3ME2xMlQxPjBzIN88US=>	NU\B[GVEW0GQR1XS
LCLC-97TM1	NFiyZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTFwNEGwOFYh\|ryP	NYCz[WFXW0GQR1XS
HCT-116	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHTcHFKSzVyPUGuOFI5PTRizszN	M4XUdXNCVkeHUh?=
ALL-PO	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjnOJdsUUN3ME2xMlQ{Pzd2IN88US=>	MmjBV2FPT0WU
EW-16	M1LOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFwNEO4OFIh\|ryP	MVzTRW5ITVJ?
NCI-H661	NF6yXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTqTWM2OD1zLkS0O\|c2KM7:TR?=	MVPTRW5ITVJ?
TE-8	M4C1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\lPGlEPTB;MT60OVU3KM7:TR?=	NXL5RoJjW0GQR1XS
TCCSUP	MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1P6T2lEPTB;MT60Olk3KM7:TR?=	MkTFV2FPT0WU
SW1990	M{jwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3THSGlEPTB;MT60O\|U{OyEQvF2=	MY\TRW5ITVJ?
UM-UC-3	M2HNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDXTWM2OD1zLkS3Olc2KM7:TR?=	NGrUPHNUSU6JRWK=
HuP-T4	NH\4NYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPtNVhyUUN3ME2xMlQ5PjB5IN88US=>	M1PucXNCVkeHUh?=
NCI-H1299	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7sSW5KSzVyPUGuOVAxQDZizszN	MWLTRW5ITVJ?
RO82-W-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUX0TFJNUUN3ME2xMlUzODhzIN88US=>	M1rwdXNCVkeHUh?=
Becker	M{CzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fGZmlEPTB;MT61NlE5PyEQvF2=	M4PxZXNCVkeHUh?=
SNU-387	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwNUKyOFEh\|ryP	NFTye3BUSU6JRWK=
CAL-85-1	NXTWbnJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPBTWM2OD1zLkWyOVk6KM7:TR?=	MnuxV2FPT0WU
647-V	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPVclRkUUN3ME2xMlU{QDhizszN	NETnZ2NUSU6JRWK=
SBC-5	NWDQ[Y85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP0TWM2OD1zLkW0OVk{KM7:TR?=	MXHTRW5ITVJ?
NCI-H23	M3TrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUOwUoRrUUN3ME2xMlU2PzF2IN88US=>	MVfTRW5ITVJ?
CGTH-W-1	NGHQO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIn0SHBKSzVyPUGuOVU5OTlizszN	M3\mOHNCVkeHUh?=
SK-N-FI	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLjTWM2OD1zLkW1PVA5KM7:TR?=	M2\jSXNCVkeHUh?=
KM-H2	M4XPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDPboRKSzVyPUGuOVY1PzRizszN	M3nPbnNCVkeHUh?=
KY821	NGHpc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTFwNU[2NVch\|ryP	MlnWV2FPT0WU
RH-1	MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DLTGlEPTB;MT61Olc3OiEQvF2=	M4PnO3NCVkeHUh?=
KYSE-270	NUPlV\|UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3X6UGlEPTB;MT61O\|QzOyEQvF2=	M3;venNCVkeHUh?=
SF539	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTnTWM2OD1zLkW3PVY6KM7:TR?=	M362bXNCVkeHUh?=
JEG-3	NUO3elhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTFwNUiwPVQh\|ryP	M4\YV3NCVkeHUh?=
SCC-25	M{Phcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFwNUi0N\|Ih\|ryP	M{LTNHNCVkeHUh?=
SW1573	M3m1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFwNkCxOVgh\|ryP	NV[xUGNGW0GQR1XS
EW-1	NVfKXpR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHlTWM2OD1zLk[xN\|UyKM7:TR?=	M4jGRnNCVkeHUh?=
YKG-1	M{HPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzNXGI6UUN3ME2xMlYyPDN6IN88US=>	MoPiV2FPT0WU
EW-11	NV\1RXppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PIcmlEPTB;MT62NVc1OSEQvF2=	NH\2bm5USU6JRWK=
DJM-1	NYLXN2tTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnBdnBKSzVyPUGuOlE5OjVizszN	NYn5TItlW0GQR1XS
Calu-3	M1:1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFwNkWyNVMh\|ryP	MofkV2FPT0WU
HT-3	NE\kfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTFwNkW2OkDPxE1?	Mn;nV2FPT0WU
NCI-H69	NYTNTGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFwNkezOFMh\|ryP	NHuxc\|hUSU6JRWK=
NCI-H2126	M1PtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DyXmlEPTB;MT62O\|c6PyEQvF2=	MnvJV2FPT0WU
RPMI-2650	NFHDd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTFwNkizNVch\|ryP	M1z0ZnNCVkeHUh?=
TE-6	M3jUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\kOFhqUUN3ME2xMlcxQDd2IN88US=>	M4OyOnNCVkeHUh?=
MDA-MB-231	NVKyTJFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnWOHFKSzVyPUGuO\|E6QTNizszN	NH\DU21USU6JRWK=
A2780	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDtWZlKSzVyPUGuO\|IzODdizszN	NF:4NYRUSU6JRWK=
GOTO	NH\KWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTFwN{O1OkDPxE1?	M4HlW3NCVkeHUh?=
KYSE-70	M2HmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3f6NGlEPTB;MT63OFQ1OiEQvF2=	Mmq3V2FPT0WU
GMS-10	NH;se5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHKTWM2OD1zLke0OlYzKM7:TR?=	MVnTRW5ITVJ?
CaR-1	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTFwN{S4NVIh\|ryP	M4HBPXNCVkeHUh?=
SW900	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnkfG1KSzVyPUGuO\|Q6QTNizszN	M1LLcHNCVkeHUh?=
BB49-HNC	M3L3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX4cnhKSzVyPUGuO\|UyPjhizszN	MUnTRW5ITVJ?
SNB75	M{X6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PWVmlEPTB;MT63OVQ6OiEQvF2=	NYD2fmlIW0GQR1XS
SK-PN-DW	NX7PTJl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2L1UWlEPTB;MT63OVY5OiEQvF2=	NFrwW29USU6JRWK=
5637	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDnXXhKSzVyPUGuO\|czPjhizszN	NI[5cJlUSU6JRWK=
BT-474	MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfwTWM2OD1zLke4NVcyKM7:TR?=	MVHTRW5ITVJ?
KM12	NIOxVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTNTWM2OD1zLke5O\|QyKM7:TR?=	Mn\tV2FPT0WU
COLO-680N	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFwOEKzPFEh\|ryP	M1z4enNCVkeHUh?=
Saos-2	NXy1UIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjQVlE4UUN3ME2xMlgzPDR3IN88US=>	NXjyWYlqW0GQR1XS
CAL-54	NUTZSWJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXvWoxNUUN3ME2xMlg{OzF\|IN88US=>	MmfiV2FPT0WU
U-118-MG	NVLJVHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfDRmhKSzVyPUGuPFQ3OjJizszN	M3fOOXNCVkeHUh?=
TGBC24TKB	M4frU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTFwOEW1NFEh\|ryP	MnfUV2FPT0WU
NCI-H2052	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTmTWM2OD1zLki2OFEh\|ryP	M4XDUHNCVkeHUh?=
BB30-HNC	NVT0[3pkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3G2U2lEPTB;MT64OlQ3OiEQvF2=	NUjkN\|ZwW0GQR1XS
KNS-81-FD	NEmwbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXO1SFhkUUN3ME2xMlg6OTZ3IN88US=>	MV7TRW5ITVJ?
HN	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1m3UGlEPTB;MT64PVU1PSEQvF2=	M{fDS3NCVkeHUh?=
ACHN	NH64WFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X0TWlEPTB;MT65NFc5PiEQvF2=	M{DEVHNCVkeHUh?=
HSC-2	M1zxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXWOYdsUUN3ME2xMlkyODl4IN88US=>	M2D6b3NCVkeHUh?=
HCC2998	MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7GVY93UUN3ME2xMlk{OzJ3IN88US=>	NUXaZ3c{W0GQR1XS
HEL	NHHJVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPZTWM2OD1zLkm0NVg1KM7:TR?=	NFzNXWtUSU6JRWK=
SW684	NIjNbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTFwOUezO\|Eh\|ryP	NELENFBUSU6JRWK=
NCI-H1693	M1\uVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPDTWM2OD1zLkm4NFg3KM7:TR?=	Mo\MV2FPT0WU
8-MG-BA	NGX5UpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHj2S\|BKSzVyPUGuPVgzOSEQvF2=	MmPNV2FPT0WU
OVCAR-8	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HW[WlEPTB;Mj6wNFI6PSEQvF2=	MVfTRW5ITVJ?
DSH1	M1zwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{myd2lEPTB;Mj6wNVc4PCEQvF2=	NULjRZI{W0GQR1XS
KYSE-520	NEPGOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrpUFFKSzVyPUKuNFIxPDlizszN	NGjj[W5USU6JRWK=
GB-1	NVP2WVR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4X6dGlEPTB;Mj6wNlU4PyEQvF2=	MnnQV2FPT0WU
RCC10RGB	M1\Ge2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnJSlE2UUN3ME2yMlA1QDdzIN88US=>	NVHxfpREW0GQR1XS
SW954	M2KyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2r2O2lEPTB;Mj6wOVA{PiEQvF2=	MVnTRW5ITVJ?
IST-MES1	MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTJwMEW1Olgh\|ryP	M37RTHNCVkeHUh?=
AU565	NWDmVW9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIL3Oo5KSzVyPUKuNFU6ODVizszN	MXHTRW5ITVJ?
CW-2	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;5d49TUUN3ME2yMlA3QDd3IN88US=>	MVHTRW5ITVJ?
TE-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K3bmlEPTB;Mj6wPVM4PyEQvF2=	NHGyeGJUSU6JRWK=
KP-4	M{DQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIG5S\|NKSzVyPUKuNVA{OTJizszN	M4e4R3NCVkeHUh?=
SNU-C2B	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV60dXNtUUN3ME2yMlExQDJ\|IN88US=>	M2rhbHNCVkeHUh?=
NCI-H1395	NWL4Z4JJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fOUWlEPTB;Mj6xNFk5PiEQvF2=	MUjTRW5ITVJ?
CAS-1	NELIcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGKx[GJKSzVyPUKuNVE2PDZizszN	NFH1SGVUSU6JRWK=
NCI-H1155	M3XBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrESmVsUUN3ME2yMlIzPjlizszN	M2HDRXNCVkeHUh?=
SK-MEL-1	NWPWUnFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{j3c2lEPTB;Mj6yPFE5OSEQvF2=	NUO5UFZXW0GQR1XS
KINGS-1	M2nsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3BTWM2OD1{LkOwNFg5KM7:TR?=	NVTuOWZQW0GQR1XS
ESS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3oTWM2OD1{LkOwOVEh\|ryP	MmjNV2FPT0WU
PANC-10-05	M{fYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYi0S5A2UUN3ME2yMlM4ODJ2IN88US=>	MX7TRW5ITVJ?
HT-1376	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTJwM{i3NFgh\|ryP	M1fRfHNCVkeHUh?=
LS-513	M1;jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTJwM{i4O\|Qh\|ryP	NHO5cGdUSU6JRWK=
KNS-42	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nBdGlEPTB;Mj6zPVExPSEQvF2=	NHfJTY5USU6JRWK=
639-V	Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoriTWM2OD1{LkSyO\|U5KM7:TR?=	NWPMUHJ5W0GQR1XS
SJRH30	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHqzbG9KSzVyPUKuOFUyPjFizszN	M1T0cXNCVkeHUh?=
SW1783	MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLoeotKSzVyPUKuOFcxPzhizszN	MWDTRW5ITVJ?
NB6	M3HZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\o[mZ4UUN3ME2yMlQ5OjhizszN	NWf5WY9QW0GQR1XS
SK-MEL-30	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJwNEi4N{DPxE1?	NUm0NXc{W0GQR1XS
HCE-4	NHuye\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULOfWJPUUN3ME2yMlQ6PDB{IN88US=>	NYj0SJJPW0GQR1XS
NB10	NVzKSpltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTJwNEm0Nlkh\|ryP	MoT2V2FPT0WU
H-EMC-SS	NFrKTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTJwNUS2OUDPxE1?	M4\C[XNCVkeHUh?=
SK-HEP-1	NEn4dIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTJwNUWyN\|Yh\|ryP	MlLJV2FPT0WU
HCC1395	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPFXpZXUUN3ME2yMlU2PjV3IN88US=>	NYDoUm14W0GQR1XS
HuCCT1	MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJwNU[zPUDPxE1?	M2S2T3NCVkeHUh?=
SiHa	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HZNmlEPTB;Mj61PFcyQSEQvF2=	NGT4SJVUSU6JRWK=
EFO-21	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHuycVBKSzVyPUKuOVg4PjRizszN	MVHTRW5ITVJ?
NCI-H1666	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJwNUmwO\|Yh\|ryP	MWTTRW5ITVJ?
UMC-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTJwNUm4Olgh\|ryP	M2\seXNCVkeHUh?=
COLO-679	NHPOTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mny1TWM2OD1{Lk[xNlM{KM7:TR?=	MXvTRW5ITVJ?
A388	NH\3SGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILDdZFKSzVyPUKuOlUzPTNizszN	Ml7iV2FPT0WU
LB2518-MEL	NW\jZWM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYj5WGQ3UUN3ME2yMlY2PDB6IN88US=>	NH7q[4NUSU6JRWK=
EW-13	NEPSVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoW1TWM2OD1{Lk[4O\|Y5KM7:TR?=	NHTUWolUSU6JRWK=
MLMA	NXHrO2VvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGL0VJhKSzVyPUKuOlg5PTZizszN	M1TPV3NCVkeHUh?=
HOP-92	M{HTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33SUmlEPTB;Mj63NFEyKM7:TR?=	MlP1V2FPT0WU
NOMO-1	NYftc3hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\VcGFQUUN3ME2yMlcyPDR{IN88US=>	MWHTRW5ITVJ?
NCI-H810	MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLsSIJqUUN3ME2yMlczOTl6IN88US=>	M3rL[nNCVkeHUh?=
769-P	NXmwc4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7BNZlvUUN3ME2yMlczOjhizszN	MXzTRW5ITVJ?
SAS	MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HjZWlEPTB;Mj63OlUh\|ryP	MmjRV2FPT0WU
M059J	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfPbYVKSzVyPUKuO\|g{OThizszN	NHrFSXNUSU6JRWK=
RD	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PWdmlEPTB;Mj63PVQ4OSEQvF2=	MnuxV2FPT0WU
GT3TKB	NG\qOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfuPXFXUUN3ME2yMlg{PDN\|IN88US=>	MlLQV2FPT0WU
MZ7-mel	NW\obmdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk[3TWM2OD1{Lki2OVAzKM7:TR?=	NILwTVJUSU6JRWK=
KYSE-510	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH30S4lKSzVyPUKuPFk2ODRizszN	NWS3d3pZW0GQR1XS
NCI-N87	MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHYTWM2OD1{LkmxPFA4KM7:TR?=	Moj6V2FPT0WU
MKN1	NFzhNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\0d4hSUUN3ME2zMlAxOTZ\|IN88US=>	NUX0O2V7W0GQR1XS
NCI-H2170	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn6xTWM2OD1\|LkCwOFUyKM7:TR?=	MlzpV2FPT0WU
OVCAR-3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnRdpNKSzVyPUOuNFIyOTVizszN	M1jrTHNCVkeHUh?=
KLE	M1rKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HnWmlEPTB;Mz6wOlgyOiEQvF2=	M4HubXNCVkeHUh?=
LB771-HNC	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTNwMEmzOFMh\|ryP	NWfMb5JOW0GQR1XS
MC116	NGPYXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonjTWM2OD1\|LkGxNVEzKM7:TR?=	NH\pdJFUSU6JRWK=
SCC-9	NFLmdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTNwMUGzOlYh\|ryP	MlfxV2FPT0WU
U031	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTNwMUK0NlMh\|ryP	NFPjNnhUSU6JRWK=
LCLC-103H	M2DweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGmzXmZKSzVyPUOuNlM5QTRizszN	NHjMXpBUSU6JRWK=
U-266	MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTNwMke2N\|Mh\|ryP	Mn3GV2FPT0WU
JVM-2	M4rXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTNwM{KxOlQh\|ryP	MYjTRW5ITVJ?
UACC-257	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTNwNE[0N\|Eh\|ryP	NGLrZWhUSU6JRWK=
LB996-RCC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XLN2lEPTB;Mz60OlUxOiEQvF2=	MonYV2FPT0WU
BT-549	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTNwNUCyNFkh\|ryP	NHvDd\|hUSU6JRWK=
NCI-H526	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NViwRpB6UUN3ME2zMlU1OTV6IN88US=>	MUjTRW5ITVJ?
RH-18	MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXITWM2OD1\|Lk[xO\|k5KM7:TR?=	MXvTRW5ITVJ?
SW626	NUXlTVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;uTWM2OD1\|LkexNVI5KM7:TR?=	NIDYVYRUSU6JRWK=
SK-N-AS	NWPyS3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTJZnZwUUN3ME2zMlc{OjR5IN88US=>	M3znXXNCVkeHUh?=
IGR-1	MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTBfGxHUUN3ME2zMlc1OjR6IN88US=>	MlvuV2FPT0WU
NCI-H2291	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHqzZ\|lKSzVyPUOuO\|U{OzZizszN	NIrGb3lUSU6JRWK=
NCI-H441	NHf5Z29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PvXWlEPTB;Mz64NlQ{OyEQvF2=	NXPPOY1YW0GQR1XS
D-247MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTNwOE[wN\|Eh\|ryP	NXTnRpNUW0GQR1XS
COLO-320-HSR	NHrqc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvKXmlKSzVyPUOuPVEzPzFizszN	MnLOV2FPT0WU
A253	NULhVoczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\IV2lEPTB;Mz65NVQ{PiEQvF2=	MmLFV2FPT0WU
HT55	NHixe3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDoboNKSzVyPUOuPVE4PzNizszN	NWPiR4RFW0GQR1XS
MZ1-PC	NFm0XFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTNwOUW4OlQh\|ryP	M4nSdHNCVkeHUh?=
RERF-LC-MS	NH7CRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHK0PGpKSzVyPUOuPVY2OjVizszN	MXzTRW5ITVJ?
SF268	NGD4dmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrxTWM2OD12LkGyPFgyKM7:TR?=	MULTRW5ITVJ?
RMG-I	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTRwMkG0OVQh\|ryP	NWf1cW9iW0GQR1XS
CFPAC-1	NV;z[4FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTRwMkG2PFUh\|ryP	MV7TRW5ITVJ?
S-117	NFr4PXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWj3N2ZOUUN3ME20MlIzODJ2IN88US=>	M{LWbXNCVkeHUh?=
NCI-H2122	NXn0WZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXkVmtQUUN3ME20MlMxQTNzIN88US=>	NVntepBxW0GQR1XS
J82	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HPb2lEPTB;ND6zN\|Q1OSEQvF2=	MmLyV2FPT0WU
CAL-72	NX;lc3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLJUoVCUUN3ME20MlM2PDd5IN88US=>	NHrzNo5USU6JRWK=
GP5d	M{nMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTRwNEGyPVgh\|ryP	MlmxV2FPT0WU
UACC-62	NYfIZlRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{H1cmlEPTB;ND60OlU1PSEQvF2=	NELUcZpUSU6JRWK=
MS-1	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYD2bpFmUUN3ME20MlQ6OTF3IN88US=>	NYr6OW5NW0GQR1XS
RCM-1	NYmyV4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfiPVBKSzVyPUSuOVI6OiEQvF2=	M2\IfnNCVkeHUh?=
IST-SL1	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTRwNkWzOVkh\|ryP	M2TVWHNCVkeHUh?=
SW756	NIe0OHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnacXVuUUN3ME20MlY6OTN3IN88US=>	M4X5PHNCVkeHUh?=
HCC38	NHzYbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkW5TWM2OD12LkexNVk4KM7:TR?=	MU\TRW5ITVJ?
YAPC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1i4[mlEPTB;ND63NVMyOyEQvF2=	NYTQ[YNIW0GQR1XS
DK-MG	M1XIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHmwV\|lKSzVyPUSuO\|gyOTJizszN	NWHIcoxKW0GQR1XS
HCC1937	MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zJfmlEPTB;ND64OVEzPSEQvF2=	NWr1cHpFW0GQR1XS
OAW-28	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHX0cnRKSzVyPUSuPVI1OzVizszN	NUfLOVVIW0GQR1XS
MEG-01	MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnCVXZ3UUN3ME21MlA5OzJ6IN88US=>	NYLLXFhCW0GQR1XS
GI-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTVwMkO0PFYh\|ryP	NVj5fGM6W0GQR1XS
FADU	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXuTWM2OD13LkK3PFM4KM7:TR?=	MkXTV2FPT0WU
CAPAN-1	NV\L[YJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TUemlEPTB;NT6zPVQ{OiEQvF2=	MkHWV2FPT0WU
TGBC11TKB	M1:1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDITWM2OD13LkS1O\|g3KM7:TR?=	Mn;XV2FPT0WU
DBTRG-05MG	NF;McVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUK2R3l5UUN3ME21MlUxPTJizszN	M{frR3NCVkeHUh?=
ONS-76	NHPkUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTVwNUW4NFEh\|ryP	M3LEWXNCVkeHUh?=
Ca-Ski	MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTVwNkK1OlYh\|ryP	MXPTRW5ITVJ?
COLO-741	NVrUSlVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;KTWM2OD13LkexPVk2KM7:TR?=	NVG5NHJtW0GQR1XS
HT-29	M4XRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\MOI9IUUN3ME21MlgxPDd3IN88US=>	MXLTRW5ITVJ?
HCC1187	M3vpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljZTWM2OD13LkixNFA5KM7:TR?=	M{nDVnNCVkeHUh?=
Capan-2	NH3MVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXXcGxKSzVyPUWuPVU6QTRizszN	NFrHflBUSU6JRWK=
NCI-H630	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnT[IpoUUN3ME22MlEyPDRzIN88US=>	NFTVR5RUSU6JRWK=
COLO-678	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTnO2RKSzVyPU[uNVUxQTJizszN	NFHNOnhUSU6JRWK=
D-502MG	NYLEVGRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTZwMUezN\|Yh\|ryP	MXvTRW5ITVJ?
NB17	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[5TWM2OD14LkK0PVQ{KM7:TR?=	M1OwWHNCVkeHUh?=
SK-MEL-24	NVHWTZVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2e4eWlEPTB;Nj6yOlQ6KM7:TR?=	MXfTRW5ITVJ?
NCI-SNU-5	NH2zbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3uSHFKSzVyPU[uNlcyOThizszN	MW\TRW5ITVJ?
D-392MG	NHniU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTZwM{OzPVkh\|ryP	M3rpTnNCVkeHUh?=
A498	MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTZwNECzNFIh\|ryP	MYrTRW5ITVJ?
OCI-AML2	NUL3cpczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTZwNEW0OFUh\|ryP	MkfJV2FPT0WU
HCC2157	NELMOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTZwNEW2NVYh\|ryP	NVvyPWN2W0GQR1XS
C3A	M4fmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3ryRWlEPTB;Nj61NlAxPCEQvF2=	MYHTRW5ITVJ?
NCI-H1650	NFfrXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTZwN{C1NlIh\|ryP	MlPyV2FPT0WU
DU-145	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rCfGlEPTB;Nj63O\|A{KM7:TR?=	NGPjdWFUSU6JRWK=
COLO-829	NUSwT4tVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jN[GlEPTB;Nj63O\|g4OyEQvF2=	MnXOV2FPT0WU
LS-1034	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTdwMES0NVIh\|ryP	NIK2VoZUSU6JRWK=
HCC1954	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFy4PY1KSzVyPUeuOFgyOzRizszN	NGjlW5NUSU6JRWK=
KURAMOCHI	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTdwNEi1N\|Mh\|ryP	NVX6VGF4W0GQR1XS
Mo-T	M1jVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnCbohQUUN3ME23MlUyPDl6IN88US=>	NWrQTGlwW0GQR1XS
OE19	NIjjU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTdwNkW1NFMh\|ryP	NGXmc5pUSU6JRWK=
COR-L105	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHjTWM2OD15LkexOFIyKM7:TR?=	NYS1fGxSW0GQR1XS
NCI-H2342	NEnYWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTdwN{G1NlEh\|ryP	MXrTRW5ITVJ?
U-87-MG	NEPicm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn76TWM2OD16LkCzN\|M1KM7:TR?=	MUDTRW5ITVJ?
MKN28	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[zZ2lEPTB;OD6xNVUyPSEQvF2=	MmjWV2FPT0WU
HT-1197	NVnBcIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRThwMkW5NFch\|ryP	MUXTRW5ITVJ?
ChaGo-K-1	M{XxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRThwM{SyOFUh\|ryP	M1zvbXNCVkeHUh?=
NCI-H226	NFLDPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRThwNESzN\|Eh\|ryP	NF3VZVdUSU6JRWK=
NCI-H2029	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrLN\|dKSzVyPUmuNFY4PTlizszN	MmXzV2FPT0WU
TE-11	M1nxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PIOWlEPTB;OT60OVU5QCEQvF2=	Moe0V2FPT0WU
ZR-75-30	NWH2ZYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljRTWM2OD17LkmyOlM1KM7:TR?=	M1LIc3NCVkeHUh?=
SW837	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXqTWM2OD1zMD6yNlk{KM7:TR?=	MVXTRW5ITVJ?
NCI-H1651	NX:wUFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvJSoJKSzVyPUGwMlI{OjZizszN	NFe0[GdUSU6JRWK=
NCI-H727	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;2fYJKSzVyPUGwMlQ1QTVizszN	MkmwV2FPT0WU
NCI-H358	NXvzXFFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnFXVdKSzVyPUGwMlg{PjVizszN	NG\XPIpUSU6JRWK=
NCI-H2087	NGPWUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTFzLkC0N\|Qh\|ryP	MUDTRW5ITVJ?
FTC-133	NFnUUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGe4bnpKSzVyPUGxMlQxPTFizszN	Ml;nV2FPT0WU
LAN-6	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF{LkGyOEDPxE1?	M1HTdXNCVkeHUh?=
NCI-H1838	NWnJTWN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknYTWM2OD1zMj61NVUyKM7:TR?=	MXXTRW5ITVJ?
Calu-6	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:xTWM2OD1zND6xNFIyKM7:TR?=	MnPyV2FPT0WU
HCC70	M4P3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDmeYJkUUN3ME2xOE41PTFizszN	MkDGV2FPT0WU
KARPAS-299	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1:5bmlEPTB;MUWuNlE2QSEQvF2=	NX70W4hXW0GQR1XS
CAL-27	M4\oV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfYRZhEUUN3ME2xOU4{QDR\|IN88US=>	M330TnNCVkeHUh?=
NCI-H82	NYX5OY5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXlTWM2OD1zNT61N\|Ih\|ryP	MnHOV2FPT0WU
no-10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f2NGlEPTB;MUWuPVM5KM7:TR?=	M4fFenNCVkeHUh?=
U251	MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33GWGlEPTB;MU[uN\|Y4PSEQvF2=	NVnZbGRoW0GQR1XS
TE-9	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIr3WHRKSzVyPUG3MlUyPjZizszN	NHexWGdUSU6JRWK=
TE-10	NFHNO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkL1TWM2OD1zOT6wOlA4KM7:TR?=	NWPXSW8xW0GQR1XS
COLO-824	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWH6WZNLUUN3ME2yNE46Ojd4IN88US=>	NEX3dVZUSU6JRWK=
HuP-T3	M2O5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTJzLkC3OFgh\|ryP	NVXFe3JKW0GQR1XS
KALS-1	NGexPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fDRmlEPTB;MkGuNVc2KM7:TR?=	NFvHSI9USU6JRWK=
L-428	M{n0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\p[I54UUN3ME2yNU41ODF4IN88US=>	M1nJUXNCVkeHUh?=
JAR	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjJeVRVUUN3ME2yNU42ODJizszN	MXHTRW5ITVJ?
DoTc2-4510	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7kcHJZUUN3ME2yN{45PDd3IN88US=>	MoHXV2FPT0WU
ABC-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJ4Lke5OVch\|ryP	NVvJW2x4W0GQR1XS
MHH-NB-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUT4UId[UUN3ME2zN{4{PDZ2IN88US=>	NEPDc\|RUSU6JRWK=
SW1463	NUnrO4JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3iTWM2OD1\|Mz65PFMh\|ryP	NUWzPVROW0GQR1XS
SW1417	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlH4TWM2OD1\|Nz6wPVUzKM7:TR?=	M1exRXNCVkeHUh?=
NB12	NXjYVoM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TxT2lEPTB;M{muOFY2PSEQvF2=	MV;TRW5ITVJ?
NY	NIPm[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\4TWM2OD12MT6zNlAyKM7:TR?=	MYTTRW5ITVJ?
H1048	MXTBdI9xfG:\|aYOgRZN{[Xl?	MUO1NFAhdk1?	M17PeFczKGh?		NWX4XGJQdmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	M1rmNVI2PzN5NUSy
H86	M4PKbGFxd3C2b4Ppd{BCe3OjeR?=	M1zHOlUxOCCwTR?=	M{PqZ\|czKGh?		NHPhcYNvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	Mm\RNlU4Ozd3NEK=
H196	NHPvWm9CeG:ydH;zbZMhSXO\|YYm=	MUK1NFAhdk1?	NYPqeXhGPzJiaB?=		NI\DUI9vcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	MUOyOVc{PzV2Mh?=
H446	NFXT[XhCeG:ydH;zbZMhSXO\|YYm=	MV:1NFAhdk1?	MWi3NkBp		MoH6cohidmOnczDBRnQuOjZ\|4pETbY5lfWOnZDDhdI9xfG:\|aYO=	NE\ENZIzPTd\|N{W0Ni=>
TFK-1	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIfLPIY4OiCq	NVnYNIpKTE2VTx?=	NWW4UoFIUUN3ME20O{BvVQ>?	NUTUPGx5OjVzNUKyOFQ>
EGI-1	NHHEfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUThN4k2PzJiaB?=	NH3PWlZFVVOR	NUfESnlwUUN3ME21N{BvVQ>?	NEfXe\|kzPTF3MkK0OC=>
OCI/AML3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[3NE4zKM7:TR?=	M2nRS\|Q5KGh?		M{XhPYVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDz[Yx2dWW2aX7pZi=>	NEHWUZkzPDd\|OUO5Ny=>
U937	MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvEU2loOC5{IN88US=>	MXe0PEBp		NEX0[llmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgd4VtfW2ndHnubYI>	M37IWVI1PzN7M{mz
MOLM13	NV\mXFFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj3U3U6OC5{IN88US=>	MUC0PEBp		MX\lcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	MX[yOFc{QTN7Mx?=
MCF7	NFjUS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fy[FIxKG6P	MmrsO\|IhcA>?	NYniPYI4TkKV	NF7oWohz\WS3Y3XzJJRp\SCSRVzQNU1u\WSrYYTl[EBqdmO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fS=>	M3TxfFI1Pjh6MES2
TamR	NEPsOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFS5PYdKSzVyPUG45qCKdk1?	NIn0NokzPDR3N{C2PS=>
MCF7-X	NWDVV4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTabopKUUN3ME2yOEBvVQ>?	MXuyOFQ2PzB4OR?=
T47D-tamR	NX;tV5BXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PaPGlEPTB;MUmgcm0>	NIPkZlAzPDR3N{C2PS=>
293T	MWXGeY5kfGmxbjDBd5NigQ>?	MkH5NlAhdk1?	MVqzJIg>		M3L0SYRqe3K3cITzJGFsfC2vZXTpZZRm\CCWSV[tTWEhe3SjYnnsbZR6NCC2cnHud4xw[2G2aX;uMEBidmRiYXP0bZZqfHl?	MXOyOFM3OzR2OR?=
SW620	M4nwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TKSFAvODBzLUGw{txO	M37aflI1KGh?		MYDpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG\|IITo[UBkd26lZX70doF1cW:wIILpd4V{	MkL1NlQ{PjN2NEm=
Huh7	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFq2XY02NTFyMDDuUS=>	MnPGNE0zPCCq	NV\FcXI2TE2VTx?=	MVrpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	M3Hkd\|I1Ojl5M{Cw
Hep3B	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HHV\|UuOTByIH7N	MYqwMVI1KGh?	NF;sO5lFVVOR	NETJOW1qdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	M4rNZVI1Ojl5M{Cw
Huh7	NGPPVllHfW6ldHnvckBCe3OjeR?=	M{C5blExOCCwTR?=	NV7vcppWOTJiaB?=	M{DvV2ROW09?	NGHONYpqdmS3Y3XzJIF2fG:yaHHnfeKh	MnnLNlQzQTd\|MEC=
U87-MG	M3zNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3noTFczKGh?		MlX5S2k2OOLCiU5ihKk4QSCwTdMg	MoHRNlQzPDl4NEC=
L3.6pl	M2\vbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\lNUDPxE1?	NFfORmY4OiCq		M{LkcolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEKPUz23O\|c3ODd?	NVvDb3FjOjR{M{OzPVk>
TE671	MX\BdI9xfG:\|aYOgRZN{[Xl?	MmHoNUDPxE1?	MnTJOFghcA>?		M4K0SYlv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGFDXC15M{e=	MnrHNlQyOzN{MUi=
RD	M4D1fWFxd3C2b4Ppd{BCe3OjeR?=	NWPpSJFvOSEQvF2=	M2DVdFQ5KGh?		NGXHfXhqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	MYCyOFE{OzJzOB?=
RMS13	MWXBdI9xfG:\|aYOgRZN{[Xl?	NFfHe4wyKM7:TR?=	MYm0PEBp		MnvxbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	MXiyOFE{OzJzOB?=
RH30	MVnBdI9xfG:\|aYOgRZN{[Xl?	MnnkNUDPxE1?	NE\2S3c1QCCq		NXzlbmpHcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhSUKWLUezOy=>	M12xV\|I1OTN\|MkG4
Hep-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{S5bFAvODFvMTFOwG0>	Ml\GNVIuQTZiaB?=		NXu3eppLcW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	MnLMNlQyODN5NEm=
SCC-9	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\pV5l6OC5yMT2xJO69VQ>?	MWGxNk06PiCq		M3nnWolv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	NYq2b49UOjRzMEO3OFk>
Hep-2	NYHrRnlwTnWwY4Tpc44hSXO\|YYm=	NGHKXW0xNjFxMD61JO69VQ>?	MUmyOEBp		Ml;SZoxw[2u\|IH3UU3JEOSCjbnSgcXRQWkN{IHHjeIl3[XSrb36=	Mn7jNlQyODN5NEm=
SCC-9	NHTXNYhHfW6ldHnvckBCe3OjeR?=	NXfHTnZ5OC5zL{CuOUDPxE1?	Mlq0NlQhcA>?		NXvi[ZN{[myxY3vzJI1VV1KFMTDhcoQhdVSRUlOyJIFkfGm4YYTpc44>	M1r2UVI1OTB\|N{S5
PANC-1	MoKzRZBweHSxc3nzJGF{e2G7	NImySYQ2ODBibl2=	NEfKSII1QCCq		M{Pjc5NmdnOrdHn6[ZMheGGwY4LlZZRq[yClYX7j[ZIh[2WubIOgeI8hemGmaX;0bIVz[XC7	NIDyZogzOzh6NkK5OC=>
RMG2	NY\zU4N7SXCxcITvd4l{KEG\|c3H5	MkOxNU0yODByIH7N	MmTQO\|IhcA>?	NYXpcodzTkKV	MYPpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?=	NHTROVAzOzZzNU[zNS=>
HAC2	MWTBdI9xfG:\|aYOgRZN{[Xl?	NYnSR\|F1OS1zMECwJI5O	M{nEflczKGh?	MWDGRnM>	MlPubY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	M{DoNVI{PjF3NkOx
HT-29	MWLBdI9xfG:\|aYOgRZN{[Xl?	M1rlZVEh\|ryP	NFK4[3Q4OiCq		M2e5PIF1fGWwdXH0[ZMhPS2IVT3pcoR2[2WmIHPlcIwh\GWjdHi=	M{TwWVIyQTR7MUKx
DLD1	NVTrbopkSXCxcITvd4l{KEG\|c3H5	MorUNUDPxE1?	MXm3NkBp		NFqyfG1ifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	MUCyNVk1QTF{MR?=
HT-29	MWfGeY5kfGmxbjDBd5NigQ>?	MVqxJO69VQ>?	NH[3NlY4OiCq		NXnveGUzcW6mdXPld{BifXSxcHjh[5khfG9iY3;u[oVzKGO7dH;wdo91\WO2aX;u	MYGyNVk1QTF{MR?=
DLD1	NYrOUY9RTnWwY4Tpc44hSXO\|YYm=	NHvHW3kyKM7:TR?=	NYPyd5VYPzJiaB?=		Mo\WbY5lfWOnczDheZRweGijZ4mgeI8h[2:wZnXyJIN6fG:ycn;0[YN1cW:w	MUGyNVk1QTF{MR?=
Rh41	NYLNO2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTNyLkegcm0>	NWLFbFBFOjF\|M{e2O\|k>
Rh18	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3O3VWlEPTB;NEGuOEBvVQ>?	M3\xNFIyOzN5Nke5
Rh30	M2r4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvGTWM2OD1zNDDuUS=>	MorqNlE{Ozd4N{m=
BT-12	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTJ2Lkegcm0>	NHnLVlgzOTN\|N{[3PS=>
CHLA-266	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLkS\|JQUUN3ME2xMlEhdk1?	M33nZlIyOzN5Nke5
TC-71	NUO2TWRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITLS5dKSzVyPUS2MlUhdk1?	NHLLR3AzOTN\|N{[3PS=>
CHLA-9	NH;ZbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO5OHlKSzVyPUG1MlMhdk1?	MXGyNVM{PzZ5OR?=
CHLA-10	NFXsW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPiR4tmUUN3ME2zMlkhdk1?	MV2yNVM{PzZ5OR?=
CHLA-258	NWPMc\|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LnNmlEPTB;MUCuOEBvVQ>?	MWSyNVM{PzZ5OR?=
GBM2	Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTRyLkegcm0>	NHv2b4IzOTN\|N{[3PS=>
NB-1643	MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;kVphPUUN3ME2zN{45KG6P	MoPlNlE{Ozd4N{m=
NB-EBc1	NWDJSGJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\2cmlEPTB;MkeuNUBvVQ>?	M3rGblIyOzN5Nke5
CHLA-90	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1izcWlEPTB;M{SuOUBvVQ>?	Ml35NlE{Ozd4N{m=
CHLA-136	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;iPJBKSzVyPUG2Nk43KG6P	M1K3bVIyOzN5Nke5
NALM-6	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33KfGlEPTB;M{KuPUBvVQ>?	NHvVc48zOTN\|N{[3PS=>
COG-LL-317	NUfSUJB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTFwMzDuUS=>	M3jIVlIyOzN5Nke5
RS4;11	NGrae3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvvSmtKSzVyPUO1JI5O	NVezWIxvOjF\|M{e2O\|k>
MOLT-4	MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojpTWM2OD16Lk[gcm0>	Mke1NlE{Ozd4N{m=
CCRF-CEM	NVHlXlByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTRwMTDuUS=>	NWf4emFLOjF\|M{e2O\|k>
Kasumi-1	NVvYOHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTFwNDDuUS=>	M2HvNVIyOzN5Nke5
Karpas-299	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGftWYtKSzVyPUKxMlchdk1?	M1nkN\|IyOzN5Nke5
Ramos-RA1	NViwNoZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\tN25yUUN3ME24MlIhdk1?	MVWyNVM{PzZ5OR?=
H838	M{jLWWZ2dmO2aX;uJGF{e2G7	M1LjO\|Eh\|ryP	M3PpVFQ5KGh?		NITvc2hqdmS3Y3XzJINmdGxiYYX0c5Bp[We7	NFW5d4MzODN4NEGxNy=>
H838	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXWwMVMh\|ryP	NYXuUFZxPzJiaB?=		MWfpcoR2[2W\|IHfyc5d1cCCrbnjpZol1cW:wIHHu[EBifXSxcHjh[5k>	MWOyNFAzQDh3NB?=
A549	M3yzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXGVFUxNTNizszN	M3vZWVczKGh?		NGfRWYhqdmS3Y3XzJIdzd3e2aDDpcohq[mm2aX;uJIFv\CCjdYTvdIhi\3l?	MlT2NlAxOjh6NUS=

... Click to View More Cell Line Experimental Data

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	+ Expand Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	+ Expand Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Formulation: Dissolved in captisol (CyDex, pH 3.0) and diluted to a final captisol concentration of 30% (w/v) Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

+ Expand

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Ethanol	3 mg/mL (6.44 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01316809	Completed	Glioblastoma Multiforme\|Anaplastic Astrocytoma\|Anaplastic Oligodendroglioma\|Malignant Glioma\|Brainstem Glioma	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	March 4 2011	Phase 1
NCT01316809	Completed	Glioblastoma Multiforme\|Anaplastic Astrocytoma\|Anaplastic Oligodendroglioma\|Malignant Glioma\|Brainstem Glioma	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	March 4 2011	Phase 1
NCT00999882	Completed	Cancer\|Advanced Hepatocellular Carcinoma	AstraZeneca	October 2009	Phase 1
NCT00999882	Completed	Cancer\|Advanced Hepatocellular Carcinoma	AstraZeneca	October 2009	Phase 1
NCT00973076	Completed	Cancer\|Solid Tumors\|Advanced Solid Malignancies	AstraZeneca	August 2009	Phase 1
NCT00973076	Completed	Cancer\|Solid Tumors\|Advanced Solid Malignancies	AstraZeneca	August 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 40 Publications

8 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 40 Publications

8 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)